Avant Immunotherapeutics Inc.

avant immunotherapeutics inc. - All News and Analysis

• Celldex Reports Third Quarter and Nine Month Financial Results

  - 2008-11-05

  - Conference Call Wednesday, November 5, at 9:00 a.m. Eastern Time - NEEDHAM, Mass. -- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the third quarter and nine-month period ended September 30, 2008. Celldex reported a net loss of $7.7 million, or $0.50 per share, for...

• Medarex Announces 2008 Third Quarter Financial Results

  - 2008-10-30

  PRINCETON, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today its financial results for the quarter ended September 30, 2008. Medarex's net loss for the quarter ended September 30, 2008 was $45.7 million, or ($0.36) per share, as compared to a net loss of $51.6 million, or...

• AVANT Immunotherapeutics Announces Name Change to Celldex Therapeutics

  - 2008-09-29

  - Anthony S. Marucci Appointed President and CEO - - Celldex to Trade Under NASDAQ Symbol CLDX Effective October 1 - NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) (the "Company"), today announced that, pursuant to a previously announced shareholder vote, the Company will change its...

• AVANT CEO To Present at the UBS 2008 Global Life Sciences Conference September 23

  - 2008-09-18

  NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Anthony S. Marucci, Interim President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will present at the UBS 2008 Global Life Sciences Conference at the Grand Hyatt New York on Tuesday, September 23, at 2:30 pm, EDT. ...

• AVANT CEO to Present at the 28th Annual Canaccord Adams Global Growth Conference

  - 2008-08-08

  NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that Anthony S. Marucci, interim President and Chief Executive Officer of AVANT Immunotherapeutics, Inc., will present at the 28th Annual Canaccord Adams Global Growth Conference at the InterContinental Hotel in Boston on Wednesday, August 13 at 4:00 pm, EDT. ...

• AVANT Reports Second Quarter and Six Month Financial Results

  - 2008-08-06

  Conference Call Wednesday, August 6 at 9:00 a.m. Eastern Time NEEDHAM, Mass. -- Please replace the release with the following corrected version due to multiple revisions. AVANT REPORTS SECOND QUARTER AND SIX MONTH FINANCIAL RESULTS Conference Call Wednesday, August 6 at 9:00 a.m. Eastern...

• AVANT to Report Second Quarter 2008 Financial Results on August 6, 2008

  - 2008-08-04

  Conference Call to Follow NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will release its second quarter 2008 financial results before U.S. financial markets open on August 6, 2008. AVANT executives will host a conference call and live audio webcast at 9:00 am ET that same...

• US pharma major Pfizer has been granted a worldwide licence for a cancer vaccine candidate CDX-110, which is currently in Phase II development for the treatment of glioblastoma multiforme, by Celldex Therapeutics, which in Q1 2008 became a subsidiary of US vaccine developer Avant Immunotherapeutics

  - 2008-06-09

  US pharma major Pfizer has been granted a worldwide licence for a cancer vaccine candidate CDX-110, which is currently in Phase II development for the treatment of glioblastoma multiforme, by Celldex Therapeutics, which in Q1 2008 became a subsidiary of US vaccine developer Avant Immunotherapeutics. CDX-110, which targets the tumour-specific...

• Market Pulse Breaking News Alert for Tuesday, June 3, 2008: NCEN – NACEL Energy Achieves Objectives With 640 MW Wind Power in Development, Sets New 1000 MW Target and Prepares for Rapid Expansion!

  - 2008-06-03

  Market Pulse News Alert for thisAM, Stocks to Watch are: NACEL Energy Corporation (OTCBB: NCEN), Acorda Therapeutics Inc. (NASDAQ: ACOR), AVANTImmunotherapeutics Inc. (NASDAQ: AVAN)and Taplmmune Inc. (OTCBB: TPIM). Investors need to be watching NACEL Energy Corporation(OTCBB: NCEN) this AM! NACEL Energy is engaged in thebusiness of generating clean, profitable, renewable...

• Updated CDX-110 Data in Glioblastoma Multiforme Presented at 44th Annual ASCO Annual Meeting

  - 2008-06-02

  Survival and Time-to-Progression Reported From Open-Label Phase II Studies CHICAGO -- AVANT Immunotherapeutics (Nasdaq: AVAN) and Pfizer, Inc. (NYSE: PFE) today announced the presentation of new data from two Phase 2 studies at the 44th Annual Meeting of the American Society of Clinical Oncology ASCO for CDX-110, an...

• Vaccine for brain tumor may double survival: study

  - 2008-06-02

  CHICAGO AFP — An experimental vaccine designed to treat the most common and deadly brain tumor has more than doubled the survival of patients, according to results of a small clinical study released on Monday. The vaccine, produced by the US firm Avant Immunotherapeutics Inc, stimulates the immune...

• AVANT Announces Temporary Postponement of Conference Call

  - 2008-05-16

  NEEDHAM, Mass. -- AVANT Immunotherapeutic (NASDAQ: AVAN) today announced that it has postponed its first-quarter 2008 financial results call due to a delay in filing its Form 10-Q for the period ended March 31, 2008. The delay is necessary for management to finalize certain technical accounting matters related to the...

• Omrix Biopharmaceuticals Announces Larry Ellberger's Appointment as Chairman of the Board and the Election of Pamela McNamara as a New Director

  - 2008-05-15

  NEW YORK -- Omrix Biopharmaceuticals, Inc. ("Omrix" or the "Company") (NASDAQ: OMRI) announced today that Larry Ellberger was named Chairman of the Board of Directors ("Board") and Pamela McNamara was elected a Director at the Company's 2008 Annual Meeting of Stockholders held today in New York City. Mr....

• AVANT to Host Conference Call Today, April 16, 2008, at 5:00 PM to Discuss CDX-110 Partnership with Pfizer

  - 2008-04-16

  NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) will hold a conference call today at 5:00 PM ET to discuss today's announcement of an exclusive worldwide licensing and development agreement between AVANT, acting through its wholly-owned subsidiary Celldex Therapeutics, Inc., and Pfizer for CDX-110. CDX-110, a therapeutic cancer vaccine candidate,...

• AVANT Resumes Trading under the Symbol "AVAN"

  - 2008-04-07

  NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today that AVANT's common stock has resumed trading under the symbol "AVAN" on the Nasdaq Global Market. Since March 10, 2008, AVANT's stock has been trading under the symbol "AVAND" to alert investors to AVANT's March 7, 2008 reverse stock split....

• FDA Approves ROTARIX® Rotavirus Vaccine

  - 2008-04-04

  NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today that its partner, GlaxoSmithKline GSK, has received approval from the U.S. Food and Drug Administration FDA for ROTARIX[R] for the prevention of rotavirus gastroenteritis in infants. With only two doses, ROTARIX will offer protection against the most commonly circulating rotavirus...

• AVANT Announces Completed Merger with Celldex and 1-for-12 Reverse Stock Split

  - 2008-03-07

  Results of Shareholder Meeting also Announced - All Resolutions Approved NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today the completed merger of Callisto Merger Corporation, its wholly-owned subsidiary, with and into Celldex Therapeutics, Inc., resulting in the combined company which will continue to be named AVANT...

• AVANT Reports Fourth Quarter and Fiscal 2007 Financial Results

  - 2008-02-27

  NEEDHAM, Mass. -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today reported financial results for the fourth quarter and year ended December 31, 2007. AVANT reported a net loss of $5.3 million, or $0.07 per share, for the fourth quarter of 2007 compared to a net loss of $6.2 million, or $0.08...

• OTCPicks.com Daily Market Movers Digest Midday Report for Thursday, February 21st RLTR, AVAN, PRCC, UMNG, AWYI.

  - 2008-02-21

  M2 PRESSWIRE-21 February 2008-OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday Report for Thursday, February 21st RLTR, AVAN, PRCC, UMNG, AWYIC1994-2008 M2 COMMUNICATIONS LTD RDATE:21022008 Our Stocks to Watch today include ReelTime Rentals, Inc. (OTC: RLTR), AVANT Immunotherapeutics, Inc. (NASD:...

• Has added AVANT Immunotherapeutics Inc. to their watch list.

  - 2008-02-21

  M2 PRESSWIRE-21 February 2008-The Maybach Review: Has added AVANT Immunotherapeutics Inc. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:21022008 Maybach Financial is a syndicate of financial informants representing a true investing experience. Taking research from financial consultants, brokers,...

• Incorporated: 1983
• CEO: Mr. Anthony S. Marucci
• Employees: 50